Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brightpoint, Inc stock logo
CELL
Brightpoint
$1.00
$2.22
$0.00
$0.00
$99.11M0.84676,796 shsN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$8.42
-5.6%
$6.95
$3.91
$13.99
$613.80M1.61817,220 shs601,634 shs
Quanterix Corporation stock logo
QTRX
Quanterix
$6.12
-4.1%
$5.45
$4.05
$16.74
$247.73M1.05590,276 shs673,718 shs
Seer, Inc. stock logo
SEER
Seer
$2.01
+1.5%
$2.03
$1.56
$2.63
$116.56M1.54328,125 shs336,523 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brightpoint, Inc stock logo
CELL
Brightpoint
0.00%0.00%0.00%0.00%0.00%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+0.68%+43.64%+42.72%+2.65%
Quanterix Corporation stock logo
QTRX
Quanterix
0.00%+3.07%+27.86%-11.63%-53.70%
Seer, Inc. stock logo
SEER
Seer
0.00%-7.04%-5.26%+5.32%+18.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Brightpoint, Inc stock logo
CELL
Brightpoint
N/AN/AN/AN/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.1917 of 5 stars
3.52.00.00.03.01.70.0
Quanterix Corporation stock logo
QTRX
Quanterix
3.275 of 5 stars
3.33.00.00.03.83.30.6
Seer, Inc. stock logo
SEER
Seer
2.7428 of 5 stars
3.03.00.00.02.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brightpoint, Inc stock logo
CELL
Brightpoint
0.00
N/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$25.67204.83% Upside
Quanterix Corporation stock logo
QTRX
Quanterix
2.50
Moderate Buy$15.60154.90% Upside
Seer, Inc. stock logo
SEER
Seer
2.00
Hold$3.0049.25% Upside

Current Analyst Ratings Breakdown

Latest CELL, EYPT, QTRX, and SEER Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$28.00
5/29/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/16/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/13/2025
Quanterix Corporation stock logo
QTRX
Quanterix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/8/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
4/30/2025
Quanterix Corporation stock logo
QTRX
Quanterix
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Quanterix Corporation stock logo
QTRX
Quanterix
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$12.00 ➝ $8.00
3/25/2025
Quanterix Corporation stock logo
QTRX
Quanterix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/25/2025
Quanterix Corporation stock logo
QTRX
Quanterix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$28.00 ➝ $18.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brightpoint, Inc stock logo
CELL
Brightpoint
$78.60M1.26N/AN/A$1.97 per share0.51
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$43.27M13.39N/AN/A$4.93 per share1.71
Quanterix Corporation stock logo
QTRX
Quanterix
$137.42M1.73N/AN/A$8.57 per share0.71
Seer, Inc. stock logo
SEER
Seer
$14.17M8.35N/AN/A$5.54 per share0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brightpoint, Inc stock logo
CELL
Brightpoint
-$98.04M-$1.55N/AN/AN/A-173.40%-73.02%-44.23%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.41N/AN/AN/A-261.91%-54.27%-41.75%8/6/2025 (Estimated)
Quanterix Corporation stock logo
QTRX
Quanterix
-$38.53M-$1.30N/AN/AN/A-36.82%-15.07%-12.26%8/6/2025 (Estimated)
Seer, Inc. stock logo
SEER
Seer
-$86.60M-$1.41N/AN/AN/A-560.90%-24.69%-22.13%8/6/2025 (Estimated)

Latest CELL, EYPT, QTRX, and SEER Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Seer, Inc. stock logo
SEER
Seer
-$0.37-$0.34+$0.03-$0.34$3.25 million$4.21 million
5/12/2025Q1 2025
Quanterix Corporation stock logo
QTRX
Quanterix
-$0.69-$0.53+$0.16-$0.53$28.27 million$30.33 million
5/7/2025Q1 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Brightpoint, Inc stock logo
CELL
Brightpoint
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Quanterix Corporation stock logo
QTRX
Quanterix
N/AN/AN/AN/AN/A
Seer, Inc. stock logo
SEER
Seer
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brightpoint, Inc stock logo
CELL
Brightpoint
N/A
2.24
1.26
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
7.85
7.79
Quanterix Corporation stock logo
QTRX
Quanterix
N/A
8.29
7.53
Seer, Inc. stock logo
SEER
Seer
N/A
19.34
18.81

Institutional Ownership

CompanyInstitutional Ownership
Brightpoint, Inc stock logo
CELL
Brightpoint
58.39%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Quanterix Corporation stock logo
QTRX
Quanterix
86.48%
Seer, Inc. stock logo
SEER
Seer
75.20%

Insider Ownership

CompanyInsider Ownership
Brightpoint, Inc stock logo
CELL
Brightpoint
17.60%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
4.46%
Quanterix Corporation stock logo
QTRX
Quanterix
6.90%
Seer, Inc. stock logo
SEER
Seer
11.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
Brightpoint, Inc stock logo
CELL
Brightpoint
N/A99.30 million81.82 millionNot Optionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.81 million65.74 millionOptionable
Quanterix Corporation stock logo
QTRX
Quanterix
46038.83 million36.15 millionOptionable
Seer, Inc. stock logo
SEER
Seer
16058.87 million52.23 millionOptionable

Recent News About These Companies

Yalburga seer’s yoga routine benefits devotees
Baba Vanga's chilling WW3 prediction
CRC Outcomes Better When First of Multiple Cancers
Seer takes the lead in Miyawaki model forest development
Surgical Outcomes in OAs With Colorectal Cancer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Brightpoint stock logo

Brightpoint NASDAQ:CELL

Brightpoint, Inc.(BrightPoint) is engaged in providing device lifecycle services to the wireless industry. The Company provides customized logistic services, including demand planning, procurement, inventory management, software loading, kitting and customized packaging, fulfillment, credit services, receivables management, call center services, activation services, Website hosting, e-fulfillment solutions, repair, refurbish and recycle services, reverse logistics, transportation management and other services within the global wireless industry. The Company's has three geographic segments, the Americas, EMEA and Asia-Pacific. Its customers include mobile network operators, mobile virtual network operators (MVNOs), resellers, retailers and wireless equipment manufacturers. In March 2011, the Company acquired the business and assets of C20 Mobile Pte. Ltd. and C20 Corporation Pte. Ltd. In October 2012, Ingram Micro Inc acquired Brightpoint.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$8.42 -0.50 (-5.61%)
Closing price 04:00 PM Eastern
Extended Trading
$8.62 +0.20 (+2.32%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Quanterix stock logo

Quanterix NASDAQ:QTRX

$6.12 -0.26 (-4.08%)
Closing price 04:00 PM Eastern
Extended Trading
$6.39 +0.27 (+4.41%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Seer stock logo

Seer NASDAQ:SEER

$2.01 +0.03 (+1.52%)
Closing price 04:00 PM Eastern
Extended Trading
$2.00 0.00 (-0.25%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.